Study Evaluating Betrixaban in Pediatric Participants

PHASE1TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

July 13, 2018

Primary Completion Date

October 8, 2019

Study Completion Date

October 8, 2019

Conditions
VTE Prophylaxis
Interventions
DRUG

Betrixaban

Factor Xa inhibitor.

Trial Locations (20)

30322

Children's Healthcare of Atlanta, Atlanta

44106

Rainbow Babies & Children's Hospital, Cleveland

70001

Tulane Medical Center, New Orleans

76000

Ivano-Frankivsk Regional Children Clinical Hospital, Ivano-Frankivsk

90027

Children's Hospital Los Angeles, Los Angeles

90036

ACTCA, Axis Clinical Trials, Los Angeles

119049

Children's City Clinical Hospital, Moscow

125412

Pirogov Russian National Research Medical University, Moscow

194100

Saint Petersburg State Pediatric Medical University, Saint Petersburg

420138

Children's Hospital of Tatarstan Republic, Kazan'

603136

State Budgetary Institution, Nizhny Novgorod

650002

Federal State Institution, Kemerovo

Unknown

Odessa Regional Children Clinical Hospital, Odesa

Sumy Regional Children's Hospital, Sumy

Vinnytsia Regional Children's Clinical Hospital, Department of Anesthesiology and Intensive Care, Vinnitsa

B4 6NH

Birmingham Women's and Children's NHS Foundation Trust, Birmingham

CB2 0QQ

Addenbrooke's Hospital, Cambridge

CF14 4XW

Children's Hospital for Wales, Cardiff

LE3 9QP

Glenfield Hospital, Leicester

SE1 7EH

Evelina London Children's Hospital, London

Sponsors
All Listed Sponsors
collaborator

Portola Pharmaceuticals, LLC (a wholly owned subsidiary of Alexion Pharmaceuticals)

INDUSTRY

lead

Alexion Pharmaceuticals, Inc.

INDUSTRY